TY - JOUR
T1 - Clinical significance of acquired cytogenetic clones in patients with treated follicular lymphoma
AU - Wang, Xiaohong I.
AU - Yin, C. Cameron
AU - Qazilbash, Muzaffar H.
AU - Hu, Shimin
AU - Lu, Gary
N1 - Publisher Copyright:
© 2015 Elsevier Inc. All rights reserved.
PY - 2015/5/1
Y1 - 2015/5/1
N2 - Abstract Background Follicular lymphoma (FL) is the second most common B-cell non-Hodgkin lymphoma worldwide. In most patients, the disease is diagnosed at advanced stages and cannot be cured using conventional therapeutic approaches. To assess the role of cytogenetic abnormalities in therapy-related myeloid neoplasms (tMNs), we studied the clinicopathologic and cytogenetic features of treated FL patients who subsequently developed a new acquired cytogenetic clone (ACC). Patients and Methods Twenty-five treated FL patients developed new cytogenetic abnormalities from 2009 to 2012. Patients were divided into 3 groups based on the presence and absence of tMNs: group 1, ACC without tMNs after a median follow-up of 15 months; group 2, ACC with possible tMN after silent ACC detection; group 3, tMNs present at the first ACC detection. Results The most frequent cytogenetic aberrations involved chromosome 7. Compared with group 1, group 3 had significantly greater size of ACC, higher frequency of chromosome 7 aberrations, more likely showed dysplasia, and lower platelet count (P =.03). Conclusion Our results indicate that the presence of ACC alone is insufficient for diagnosis of tMNs. The proportion of cells with specific aberrations at first ACC, bone marrow dysplasia, and low platelet counts might predict outcome of ACC.
AB - Abstract Background Follicular lymphoma (FL) is the second most common B-cell non-Hodgkin lymphoma worldwide. In most patients, the disease is diagnosed at advanced stages and cannot be cured using conventional therapeutic approaches. To assess the role of cytogenetic abnormalities in therapy-related myeloid neoplasms (tMNs), we studied the clinicopathologic and cytogenetic features of treated FL patients who subsequently developed a new acquired cytogenetic clone (ACC). Patients and Methods Twenty-five treated FL patients developed new cytogenetic abnormalities from 2009 to 2012. Patients were divided into 3 groups based on the presence and absence of tMNs: group 1, ACC without tMNs after a median follow-up of 15 months; group 2, ACC with possible tMN after silent ACC detection; group 3, tMNs present at the first ACC detection. Results The most frequent cytogenetic aberrations involved chromosome 7. Compared with group 1, group 3 had significantly greater size of ACC, higher frequency of chromosome 7 aberrations, more likely showed dysplasia, and lower platelet count (P =.03). Conclusion Our results indicate that the presence of ACC alone is insufficient for diagnosis of tMNs. The proportion of cells with specific aberrations at first ACC, bone marrow dysplasia, and low platelet counts might predict outcome of ACC.
KW - Bone Marrow Dysplasia
KW - Fluorescent In Situ Hybridization (FISH)
KW - Platelet Count
KW - Silent Acquired Cytogenetic Clone
KW - Therapy-Related Myeloid Neoplasm
UR - http://www.scopus.com/inward/record.url?scp=84928272083&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84928272083&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2014.12.004
DO - 10.1016/j.clml.2014.12.004
M3 - Article
C2 - 25573378
AN - SCOPUS:84928272083
SN - 2152-2650
VL - 15
SP - 262
EP - 269
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
IS - 5
M1 - 526
ER -